{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Physician%27s+Choice+of+Endocrine+Therapy", "query": { "intervention": "Physician's Choice of Endocrine Therapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Physician%27s+Choice+of+Endocrine+Therapy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-06T17:00:10.812Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05840211", "title": "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced or Unresectable Metastatic Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 654, "start_date": "2023-05-08", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-10-06T17:00:10.812Z", "location_count": 30, "location_summary": "Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05840211" }, { "nct_id": "NCT05467891", "title": "Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locoregional Recurrence", "Hormone Receptor-positive Breast Cancer", "HER2-negative Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oana Danciu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2022-09-13", "completion_date": "2029-08-15", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-06T17:00:10.812Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Washington D.C., District of Columbia + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05467891" }, { "nct_id": "NCT03219476", "title": "Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Invasive Breast Cancer" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 37, "start_date": "2017-02-05", "completion_date": "2025-03-20", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-06T17:00:10.812Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03219476" }, { "nct_id": "NCT05306340", "title": "A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "Giredestrant", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "LHRH Agonist", "type": "DRUG" }, { "name": "Dexamethasone Mouth Rinse", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 373, "start_date": "2022-08-03", "completion_date": "2026-10-15", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-06T17:00:10.812Z", "location_count": 55, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 47 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05306340" }, { "nct_id": "NCT04961996", "title": "A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Early Breast Cancer" ], "interventions": [ { "name": "Giredestrant", "type": "DRUG" }, { "name": "Physician's Choice of Endocrine Therapy", "type": "DRUG" }, { "name": "LHRH Agonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4170, "start_date": "2021-08-27", "completion_date": "2033-09-30", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-06T17:00:10.812Z", "location_count": 72, "location_summary": "Daphne, Alabama • Bakersfield, California • Fullerton, California + 66 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04961996" }, { "nct_id": "NCT07214532", "title": "Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Neoplasms", "Carcinoma, Ductal, Breast", "Receptors, Estrogen (for ER-positive Requirement)" ], "interventions": [ { "name": "ctDNA-Guided Treatment Strategy", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Natera, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 725, "start_date": "2026-05-08", "completion_date": "2037-12-30", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-06T17:00:10.812Z", "location_count": 49, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07214532" }, { "nct_id": "NCT05826964", "title": "Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "ER-positive Breast Cancer", "HER2-negative Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "AI+CDK4/6i", "type": "DRUG" }, { "name": "SERD+CDK4/6i", "type": "DRUG" }, { "name": "mTOR inhibitor + AI", "type": "DRUG" }, { "name": "mTOR inhibitor + SERD", "type": "DRUG" }, { "name": "mTOR inhibitor + Selective estrogen receptor modulator", "type": "DRUG" }, { "name": "PI3K inhibitor + SERD", "type": "DRUG" }, { "name": "PI3K inhibitor + AI", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Oral SERD", "type": "DRUG" }, { "name": "PARPi", "type": "DRUG" }, { "name": "AKT inhibitor", "type": "DRUG" }, { "name": "Step 3 Arm 2", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2023-06-12", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-10-06T17:00:10.812Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05826964" }, { "nct_id": "NCT07391774", "title": "Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Estrogen Receptor-Positive Breast Carcinoma", "HER2-Negative Breast Carcinoma" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Oncotype DX Breast Cancer Assay", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Ribociclib Succinate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1978, "start_date": "2026-08-10", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-06T17:00:10.812Z", "location_count": 200, "location_summary": "Jonesboro, Arkansas • Auburn, California • Berkeley, California + 166 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Auburn", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07391774" }, { "nct_id": "NCT04576455", "title": "A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "Giredestrant", "type": "DRUG" }, { "name": "Fulvestrant or an Aromatase Inhibitor (Physician Choice)", "type": "DRUG" }, { "name": "LHRH Agonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 303, "start_date": "2020-11-27", "completion_date": "2027-08-25", "has_results": true, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-06T17:00:10.812Z", "location_count": 3, "location_summary": "Marietta, Georgia • Cleveland, Ohio • Tigard, Oregon", "locations": [ { "city": "Marietta", "state": "Georgia" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Tigard", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04576455" }, { "nct_id": "NCT06380751", "title": "Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Breast Cancer" ], "interventions": [ { "name": "Saruparib (AZD5305)", "type": "DRUG" }, { "name": "Camizestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 788, "start_date": "2024-08-01", "completion_date": "2031-12-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-06T17:00:10.812Z", "location_count": 57, "location_summary": "Gilbert, Arizona • Fountain Valley, California • Glendale, California + 49 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06380751" } ] }